miR-1205/DNAJB1 reverses docetaxel chemoresistance in human triple negative breast carcinoma cells via regulation of mutp53/TAp63 signaling
Chemoresistance is the major cause of therapeutic failure in human triple negative breast carcinoma (TNBC). Docetaxel (DOC), a first-line therapeutic drug in TNBC treatment, is limited for long-term use due to the development of chemoresistance. Thus, overcoming chemoresistance of DOC remains an imp...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Science Publishing & Media Ltd.
2021-12-01
|
Series: | Acta Biochimica et Biophysica Sinica |
Subjects: | |
Online Access: | https://www.sciengine.com/doi/10.3724/abbs.2021006 |